8-KMaterial Agreements

ALNYLAM PHARMACEUTICALS, INC. 8-K Report, Material Agreement (Sep 12, 2007)

Filed September 12, 2007For Securities:ALNY

Summary

This 8-K filing by Alnylam Pharmaceuticals, Inc. (ALNY) on September 12, 2007, announces the entry into a material definitive agreement. Specifically, the company entered into a strategic alliance with Sanofi-Aventis, a global pharmaceutical leader. This agreement grants Sanofi-Aventis a worldwide license to develop and commercialize ALNY's RNAi therapeutic candidate, ALN-RSV01, which is being investigated for the treatment of respiratory syncytial virus (RSV) infection. The partnership is significant for Alnylam as it validates their RNA interference (RNAi) platform and provides substantial financial backing. The deal includes an upfront payment, potential milestone payments, and royalties on future sales. This agreement represents a key step in advancing ALN-RSV01 through clinical development and towards potential commercialization, leveraging Sanofi-Aventis's global reach and expertise in infectious diseases. Investors should note this as a positive development, demonstrating Alnylam's ability to secure high-value partnerships with major pharmaceutical players.

Key Highlights

  • 1Alnylam Pharmaceuticals entered into a material definitive agreement with Sanofi-Aventis.
  • 2The agreement grants Sanofi-Aventis a worldwide license to develop and commercialize ALN-RSV01.
  • 3ALN-RSV01 is an RNAi therapeutic candidate for the treatment of respiratory syncytial virus (RSV) infection.
  • 4The deal includes an upfront payment to Alnylam Pharmaceuticals.
  • 5Potential milestone payments and royalties on future sales are also part of the agreement.
  • 6This partnership validates Alnylam's RNAi platform and its potential for therapeutic development.
  • 7The collaboration leverages Sanofi-Aventis's expertise in infectious diseases and global commercial capabilities.

Frequently Asked Questions

Alnylam Pharmaceuticals has entered into a strategic alliance with Sanofi-Aventis, granting Sanofi-Aventis a worldwide license to develop and commercialize Alnylam's RNAi therapeutic candidate, ALN-RSV01.

ALN-RSV01 is an RNA interference (RNAi) therapeutic candidate being investigated for the treatment of respiratory syncytial virus (RSV) infection.

The agreement includes an upfront payment to Alnylam Pharmaceuticals. Additionally, Alnylam is eligible to receive potential milestone payments based on the development and commercial success of ALN-RSV01, as well as royalties on future sales.

This partnership is significant because it validates Alnylam's RNAi platform technology and provides substantial financial resources. It also allows Alnylam to leverage Sanofi-Aventis's extensive experience and global infrastructure in infectious diseases for the development and potential commercialization of ALN-RSV01.